441 related articles for article (PubMed ID: 27084245)
21. The Association of County-level Prostate-specific Antigen Screening with Metastatic Prostate Cancer and Prostate Cancer Mortality.
Stone BV; Labban M; Beatrici E; Filipas DK; D'Amico AV; Lipsitz SR; Choueiri TK; Kibel AS; Cole AP; Iyer HS; Trinh QD
Eur Urol Oncol; 2024 Jun; 7(3):563-569. PubMed ID: 38155059
[TBL] [Abstract][Full Text] [Related]
22. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
23. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
24. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen screening and mortality from prostate cancer.
Marcella SW; Rhoads GG; Carson JL; Merlino F; Wilcox H
J Gen Intern Med; 2008 Mar; 23(3):248-53. PubMed ID: 18172740
[TBL] [Abstract][Full Text] [Related]
26. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
Howard K; Barratt A; Mann GJ; Patel MI
Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
[TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R; Gore JL; Etzioni R
Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
[TBL] [Abstract][Full Text] [Related]
28. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial.
Labrie F; Candas B; Dupont A; Cusan L; Gomez JL; Suburu RE; Diamond P; Lévesque J; Belanger A
Prostate; 1999 Feb; 38(2):83-91. PubMed ID: 9973093
[TBL] [Abstract][Full Text] [Related]
29. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.
Hugosson J; Carlsson S; Aus G; Bergdahl S; Khatami A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Lancet Oncol; 2010 Aug; 11(8):725-32. PubMed ID: 20598634
[TBL] [Abstract][Full Text] [Related]
30. Screening and prostate-cancer mortality in a randomized European study.
Schröder FH; Hugosson J; Roobol MJ; Tammela TL; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis LJ; Recker F; Berenguer A; Määttänen L; Bangma CH; Aus G; Villers A; Rebillard X; van der Kwast T; Blijenberg BG; Moss SM; de Koning HJ; Auvinen A;
N Engl J Med; 2009 Mar; 360(13):1320-8. PubMed ID: 19297566
[TBL] [Abstract][Full Text] [Related]
31. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?
Sirovich BE; Schwartz LM; Woloshin S
JAMA; 2003 Mar; 289(11):1414-20. PubMed ID: 12636464
[TBL] [Abstract][Full Text] [Related]
32. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen testing of older men.
Carter HB; Landis PK; Metter EJ; Fleisher LA; Pearson JD
J Natl Cancer Inst; 1999 Oct; 91(20):1733-7. PubMed ID: 10528023
[TBL] [Abstract][Full Text] [Related]
35. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States.
Garraway IP; Carlsson SV; Nyame YA; Vassy JL; Chilov M; Fleming M; Frencher SK; George DJ; Kibel AS; King SA; Kittles R; Mahal BA; Pettaway CA; Rebbeck T; Rose B; Vince R; Winn RA; Yamoah K; Oh WK
NEJM Evid; 2024 May; 3(5):EVIDoa2300289. PubMed ID: 38815168
[TBL] [Abstract][Full Text] [Related]
36. Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer.
Iyer HS; Stone BV; Roscoe C; Hsieh MC; Stroup AM; Wiggins CL; Schumacher FR; Gomez SL; Rebbeck TR; Trinh QD
JAMA Netw Open; 2024 Jun; 7(6):e2414582. PubMed ID: 38833252
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
38. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.
Gulati R; Mariotto AB; Chen S; Gore JL; Etzioni R
J Clin Epidemiol; 2011 Dec; 64(12):1412-7. PubMed ID: 22032753
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
Roobol MJ; Kerkhof M; Schröder FH; Cuzick J; Sasieni P; Hakama M; Stenman UH; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis L; Recker F; Berenguer A; Ruutu M; Kujala P; Bangma CH; Aus G; Tammela TL; Villers A; Rebillard X; Moss SM; de Koning HJ; Hugosson J; Auvinen A
Eur Urol; 2009 Oct; 56(4):584-91. PubM
